In addition, we confirmed that PSMAb could inhibit tumor growth through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in PSMA+ castration-resistant prostate cancer cell xenografts in vivo (55). This evidence concerns the gene FOLH1 and prostate carcinoma.